Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

  1. Alain R. Thierry
  2. Brice Pastor
  3. Ekaterina Pisareva
  4. Francois Ghiringhelli
  5. Olivier Bouché
  6. Christelle De La Fouchardière
  7. Julie Vanbockstael
  8. Denis Smith
  9. Eric François
  10. Mélanie Dos Santos
  11. Damien Botsen
  12. Stephen Ellis
  13. Marianne Fonck
  14. Thierry André
  15. Emmanuel Guardiola
  16. Faiza Khemissa
  17. Benjamin Linot
  18. J. Martin-Babau
  19. Yves Rinaldi
  20. Eric Assenat
  21. Lea Clavel
  22. Sophie Dominguez
  23. Celine Gavoille
  24. David Sefrioui
  25. Veronica Pezzella
  26. Caroline Mollevi
  27. Marc Ychou
  28. Thibault Mazard

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1001/jamanetworkopen.2021.24483
  2. ScreenIT

    SciScore for 10.1101/2021.03.17.21253408: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: After they give written informed consent, patients are screened through a blood-sampling procedure to determine their RAS and BRAF tumor status according to plasma analysis of circulating cell free DNA, using Intplex technology20,21.
    RandomizationThe PANIRINOX study is a first line randomized phase II study, assessing the activity of a combination chemotherapy with fluorouracil, leucovorin, oxaliplatin and panitumumab ± irinotecan (FOLFOX + panitumumab vs FOLFIRINOX + panitumumab) in unresectable mCRC patients, selected by RAS and B-RAF status obtained from cirDNA analysis.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT02980510RecruitingComparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.03.17.21253408v1 on medRxiv